Affimed Immuno-Oncology Immune Cell Engagers 2016

Affimed N.V. presents its bi- and trispecific antibody platform designed to engage NK cells and T cells for tumor elimination. The Nasdaq-listed biotech company, headquartered in Heidelberg, discusses its clinical and preclinical pipeline and strategic partnerships across industry and academia.